GSK Buys Aiolos Bio for Up to $1.4 Billion
09 Janeiro 2024 - 4:39AM
Dow Jones News
By Christian Moess Laursen
GSK said it has bought Aiolos Bio, a biopharmaceutical company
focused on patients with respiratory and inflammatory conditions,
for an upfront consideration of $1.0 billion, with the potential
for an additional $400 million.
Write to Christian Moess Laursen at christian.moess@wsj.com
(END) Dow Jones Newswires
January 09, 2024 02:24 ET (07:24 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
GSK (NYSE:GSK)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
